|
|
|
|
-
Research
Dr. Smith studies the role of apelin and its receptor in cardiovascular function.
-
Biography
Dr. Smith received his Ph.D. in Pharmacology in 2002 from Vanderbilt University, Nashville, Tennessee.
Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.
Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao FF
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12
Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis.
Smith LH, Dixon JD, Stringham JR, Eren M, Elokdah H, Crandall DL, Washington K, Vaughan DE
Blood. 2006 Jan 1;107(1):132-4
Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease.
De Taeye B, Smith LH, Vaughan DE
Curr Opin Pharmacol. 2005 Apr;5(2):149-54
The sterol response element binding protein regulates cyclooxygenase-2 gene expression in endothelial cells.
Smith LH, Petrie MS, Morrow JD, Oates JA, Vaughan DE
J Lipid Res. 2005 May;46(5):862-71
Recent Options
Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor.
Maloney PR, Khan P, Hedrick M, Gosalia P, Milewski M, Li L, Roth GP, Sergienko E, Suyama E, Sugarman E, Nguyen K, Mehta A, Vasile S, Su Y, Stonich D, Nguyen H, Zeng FY, Novo AM, Vicchiarelli M, Diwan J, Chung TD, Smith LH, Pinkerton AB
Bioorg Med Chem Lett. 2012 Nov 1;22(21):6656-60
View All Publications
Layton Smith's Research Focus
Cardiovascular Diseases, Atherosclerosis, Hypertension, Metabolic Syndrome
 Watch Dr. Smith describe his research
The Smith lab focuses on identifying molecular mechanisms of increased risk for cardiovascular disease in the metabolic syndrome, by studying apelin, a vasoactive peptide that increases cardiac contractility and decreases vascular tone to reduce blood pressure. Paradoxically, this vasoprotective peptide is over-produced by fat in obese people, but fails to elicit the positive effects on the cardiovascular system. To address this paradoxical effect, Smith employs molecular biology, cellular and animal models, novel pharmacologic tools and is currently developing cell-based assays to identify small molecule probes of the apelin receptor using a HTS strategy.
About Layton Smith
Experience
Layton Smith, Ph.D., received his Doctorate degree (Pharmacology, 2002) from Vanderbilt University, Nashville, Tennessee, where he also received his postdoctoral training in Clinical Pharmacology and Cardiovascular Medicine. Dr. Smith is a Florida native and returned to his home state in 2005, to join The Scripps Research Institute in Jupiter, Florida, as an Assistant Professor in the Biomedical Sciences program, as well as Associate Director of Pharmacology. He was recruited to the position of Assistant Professor at Sanford-Burnham Medical Research Institute in 2007, where he also serves as the Director of the Pharmacology core service.
|
|
|
|
|
|